Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report by Tisman, Glenn & Garcia, April
CASE REPORT Open Access
Control of prostate cancer associated with
withdrawal of a supplement containing folic acid,
L-methyltetrahydrofolate and vitamin B12: a case
report
Glenn Tisman
* and April Garcia
Abstract
Introduction: This is the first report of possible direct stimulation of hormone-resistant prostate cancer or
interference of docetaxel cytotoxicity of prostate cancer in a patient with biochemical relapse of prostatic-specific
antigen. This observation is of clinical and metabolic importance, especially at a time when more than 80 countries
have fortified food supplies with folic acid and some contemplate further fortification with vitamin B12.
Case presentation: Our patient is a 71-year-old Caucasian man who had been diagnosed in 1997 with prostate
cancer, stage T1c, and Gleason score 3+4 = 7. His primary treatment included intermittent androgen deprivation
therapy including leuprolide + bicalutamide + deutasteride, ketoconazole + hydrocortisone, nilandrone and
flutamide to resistance defined as biochemical relapse of PSA. While undergoing docetaxel therapy to treat a
continually increasing prostate-specific antigen level, withdrawal of 10 daily doses of a supplement containing 500
μg of vitamin B12 as cyanocobalamin, as well as 400 μg of folic acid as pteroylglutamic acid and 400 μg of L-5-
methyltetrahydrofolate for a combined total of 800 μg of mixed folates, was associated with a return to a normal
serum prostatic-specific antigen level.
Conclusion: This case report illustrates the importance of the effects of supplements containing large amounts of
folic acid, L-5-methyltetrahydrofolate, and cyanocobalamin on the metabolism of prostate cancer cells directly and/
or B vitamin interference with docetaxel efficacy. Physicians caring for patients with prostate cancer undergoing
watchful waiting, hormone therapy, and/or chemotherapy should consider the possible acceleration of tumor
growth and/or metastasis and the development of drug resistance associated with supplement ingestion. We
describe several pathways of metabolic and epigenetic interactions that could affect the observed changes in
serum levels of prostate-specific antigen.
Introduction
The clinical course of our patient with hormone-refrac-
tory or hormone-resistant prostate cancer appears to
have been affected by ingestion followed by withdrawal
of a vitamin supplement containing a mixture of large
amounts of folic acid (FA), L-methyltetrahydrofolate (L-
methyl-THF, or folate) and cyanocobalamin (vitamin
B12). Prior to supplement withdrawal, the patient had
been treated with docetaxel for 18 weeks but had a
continuous rise in serum prostatic-specific antigen
(PSA) levels. Only after withdrawal of the supplement
did the patient’s elevated serum PSA level return to nor-
mal (from 22 ng/mL to 2.08 ng/mL).
Biological and clinical background
In 1946, Lewisohn et al. [1] reported the effects of pter-
oylglutamic acid (teropterin) and FA (defined as liver
Lactobacillus casei factor) on mice with spontaneous
breast cancer. Careful examination of their results
revealed that the newly discovered FA stimulated, in a
dose-dependent fashion, the growth and metastasis of
spontaneous murine breast tumors and shortened
* Correspondence: glennmd@gmail.com
Whittier Cancer Research Building, 13025 Bailey Street, Whittier, CA 90601,
USA
Tisman and Garcia Journal of Medical Case Reports 2011, 5:413
http://www.jmedicalcasereports.com/content/5/1/413 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Tisman and Garcia; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.overall survival. Two years later Heinle and Welch [2]
reported FA stimulation of chronic myelogenous leuke-
mia (CML) in three patients so inflicted. In 1948, Farber
[3] referred to an “acceleration phenomenon” observed
while treating 10 children with leukemia with pteroyl-
glutamic acid (diopterin) and teropterin. In 1950, Skip-
per et al. [4] reported that large doses of FA alone and
in combination with aminopterin modulated the survival
of mice with the transplanted acute Ak4 strain of leuke-
mia. He surmised that FA is a rate-controlling factor in
Ak4 leukemia. An excess of FA clearly accelerated the
leukemic process, causing the animals to die before
untreated controls. Acceleration of CML by vitamin B12
in patients with pernicious anemia was reported by Cor-
cino et al. in 1971 [5] and Green in 1994 [6]. In 2009,
Tisman et al. [7] presented evidence for the acceleration
of prostate cancer dedifferentiation during vitamin B12
depletion and prostate cancer acceleration in response
to vitamin B12 administration in a patient with localized
prostate cancer and pernicious anemia. In 2009, Figueir-
edo et al. [8] reported the results of a large, randomized,
controlled clinical trial carried out over 10 years in
which a group of men received 1000 μg of oral FA daily.
They observed a near tripling of the incidence of pros-
tate cancer compared to controls. Finally, a report by
Lawson et al. [9] published in 2007 described a direct
relationship between prostate cancer stage and multivi-
tamin use. During that period, most multivitamins con-
tained an additional 400 μg of FA.
Case presentation
Our patient is a 71-year-old Caucasian man who had
been diagnosed in 1997 with prostate cancer. His base-
line PSA level was 8 ng/mL. All six biopsy cores con-
tained 90% Gleason scores of 3+4 = 7 adenocarcinoma,
and peri-neural invasion was observed. The patient’s
clinical stage was T1c. He elected therapy with intermit-
tent androgen deprivation (IAD) with flutamide, leupro-
lide, and finasteride. In 2007, after the third cycle of
IAD, his PSA level slowly increased into the 3 ng/mL
range and his serum testosterone remained < 20 ng/dl.
Sequential anti-androgen withdrawal, ketoconazole,
diethylstilbestrol, estramustine, and transdermal b-estra-
diol, along with a trial of low-dose oral cyclophospha-
mide and capecitabine, all while he was being treated
with leuprolide maintenance therapy, were either transi-
ently effective or unsuccessful.
The patient was restaged, with a bone scan and com-
puted tomography yielding only evidence of biochemical
PSA relapse. He then received docetaxel 30 mg/m
2 for
three of every four weeks while his leuprolide treatment
was continued. His PSA level continued to rise expo-
nentially for 18 weeks, thus we assumed docetaxel resis-
tance. The patient revealed that he was ingesting a
supplement of 10 daily dose units of Intrinsi B12/folate
(Metagenics, San Clemente, CA, USA. Each dose unit
contained 20 mg of porcine intrinsic factor and 500 μg
of vitamin B12, as well as 400 μgo fF A ,a n d4 0 0μgo f
L-5-methyltetrahydrofolate (for a total of 800 μgo f
mixed FAs). On 11 February 2010, his PSA level reached
21.3 ng/mL, and on 25 February 2010, his serum FA
level was assayed to be 134 ng/mL (normal range 5 ng/
mL to 24 ng/mL), his serum vitamin B12 level was >
1500 pg/mL (normal range 300 pg/mL to 900 pg/mL),
his serum testosterone level was < 20 ng/mL (normal
range 212 ng/mL to 755 ng/mL), and his total serum
homocysteine was 12.0 μmol/L (normal range 7 μmol/L
to 12 μmol/L).
The patient discontinued the oral supplement on day
900 (Figure 1), and within two weeks his serum PSA
level started to decline. At the time of this writing, his
PSA level is 2.08 ng/mL. He continues to receive weekly
docetaxel chemotherapy. His last serum FA level was
4.0 ng/mL (borderline deficient), his serum vitamin B12
level was 377 pg/mL, and his total serum homocysteine
level was 17.8 μmol/L.
Discussion
High-dose folate, FA, and vitamin B12 metabolic interac-
tions may have modulated this patient’sr e s p o n s et o
PSA treatment. Figure 2 summarizes folate and B vita-
min biochemistry as they relate to the de novo and sal-
vage pathways of DNA-thymine (DNA-T) and
epigenetic regulatory effects of CH3 group transfer to
the universal methylator S-adenosylmethionine (SAM)
by FA and its vitamers.
Some metabolic consequences of high-dose FA
Figure 2 illustrates the “untrapping” of L-methyl-THF by
vitamin B12. This untrapping regenerates active reduced
folate as tetrahydrofolate (THF). DNA-T formation is
dependent on 5,10-methylene-THF, which passes its
CH3 group to deoxyuridine monophosphate, thus form-
ing thymidine monophosphate (TMP). TMP is subse-
quently phosphorylated, forming thymidine
triphosphate, which is incorporated into DNA as DNA-
T. In the absence of adequately reduced folates, uracil
rather than thymine is incorporated into DNA, thus
affecting DNA and its synthesis. Incorporated uracil
leads to gene point mutations and may initiate malig-
nant transformation. FA interference of dihydrofolate
reductase (DFR) and polymorphisms of methyltetrahy-
drofolate reductase L-methyl-THF (MTHFR), that is,
MTHFR 667TT, inhibits generation of 5-methyltetrahy-
drofolate reductase (5-methyl-THF). Pyridoxine (vitamin
B6)e x e r t si t si n f l u e n c ei np a r tt h r o u g hs e r i n eh y d r o x y -
methyltransferase (SHMT), the activity of which directs
5,10-methylene-THF in the direction of the de novo
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Page 2 of 7synthesis of DNA-T, thus minimizing the misincorpora-
tion of uracil into DNA.
FA is not naturally found in nature. In 1998, the US
government mandated that the food supply be fortified
with FA in an attempt to prevent neural tube birth
defects. This action was associated with a tripling of the
median normal serum folate level. However, FA has
3000-fold less affinity for DFR compared to dihydrofo-
late (DHF) [10], and its presence in high concentrations
may induce steric interference, thus thwarting the
reduction of natural DHF to THF and limiting the sup-
ply of reduced folates. In the USA, eating a normal diet
while ingesting a multivitamin such as Centrum Silver
(Pfizer Consumer Healthcare, Madison, NJ USA) is
commonly associated with hypervitaminosis of FA to
levels demonstrated to be associated with unnatural cir-
culating levels of FA. In our practice, new patient serum
folate levels usually exceed 25 ng/mL and are occasion-
ally > 100 ng/mL. Ingestion of large amounts of FA
affects the intra-cellular mix of folate vitamers from
methyl-THF to non-methyl-THF [11,12]. Lucock and
Yates [12] and others have proposed that the intra-cellu-
lar balance between the use of methylene-THF for
DNA-T rather than for methionine synthesis may
depend on the presence of both the MTHFR 677T poly-
morphism and high serum levels of FA. They noted that
prolonged administration of large doses of FA is asso-
ciated with greater reductions in intra-cellular concen-
trations of methylene, methenyl, formyl, and
unsubstituted folate, while generation of vitamin B12-
dependent, MTHFR-catalyzed methyl-THF levels
decreased (Figure 2). The biological consequences of
such a shift have not been thoroughly studied.
Other important metabolic interactions demon-
strated by Smulders et al. [13] involving vitamin B12
and reduced folates included the folate and vitamin
B12 dependence of the conversion of homocysteine to
methionine minimizing toxic homocysteine while gen-
erating the universal methylator/epimethylator SAM.
Changes in the SAM/S-adenosylhomocysteine (SAM/
SAH) ratio due to changes in FA/folate concentra-
tions, as well as the presence of hypersufficiency or
insufficiency of vitamin B12,v i t a m i nB 6,a n dr i b o f l a v i n
(vitamin B2), may modulate the activity of folate vita-
mers. MTHFR and its many polymorphisms have pro-
found effects as well [14,15]. High doses of both
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Figure 1 The clinical course of our patient’s prostatic-specific antigen response.
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MTHFR co-factor flavin adenine dinucleotide (FAD)
to MTHFR and its MTHFR 677T polymorphism. This
FAD co-factor binding is weakened in the MTHFR
(TT) and MTHFR (CT) polymorphisms, producing
60% and 30% less efficient heat-labile enzymes,
respectively. The heterozygous MTHFR (CT) is pre-
sent in about 40% of the US population, while two
copies of the MTHFR (TT) allele are present in about
10% of the US population.
The concentrations of B vitamins and the presence of
various coenzyme polymorphisms eventually affect gene
expression and tumor behavior. Collin et al.f o u n dt h a t
higher serum folate levels are associated with increased
risk [16] and faster progression [17] of localized prostate
cancer.
FA and epigenetic modifications in prostate cancer
The link between heritable epimethylation of cytosine
bases within promoter cytosine-phosphate-guanosine
Figure 2 Metabolic interactions between folates and vitamins B12,B 6,a n dB 2. 677C ® T thermolabile polymorphism with weakened
interaction with B2 NAD cofactor disables MTHFR function by up to 70% in homozygotes. 15% of population is homozygous (2 inherited genes)
50% is heterozygous (one inherited gene). In the presence of this mutation (677C ® T) when folate is plentiful this pathway provides adequate
SAM for DNA methylation maintenance and shunts more 5,10 methylene THF to support DNA synthesis with less Uracil misincorporation into
DNA with less 50% decreased incidence of colon cancer and acute lymphocytic leukaemia. However, in the presence of the mutation, if folate is
low, then SAM DNA methylation may increase OR decrease and de novo DNA thymidine synthesis may decrease. There is disruption of normal
intracellular methylated folate forms and all or some of these perturbations favour increased incidence of colon, breast, gastric, cervical and
prostate cancer. Under most circumstances DNA synthesis through dTMP generation takes precedence over SAM DNA methlyation. Serine
Hydroxymethyltransferase (SHMT) recently found to shift folate metabolism in the direction favoring de novo dTMP - DNA synthesis. B2 found to
modulate (lessen) effects of MTHFR polymorphisms. Diet and all B vitamin levels modulate various folate pathways and therefore risks for
malignancy!. Newly noted polymorphisms of DHFR (rs1677693 & rs1643659) have 30% decreased risk while MTR polymorphism (rs4659744) has
25% decreased risk of colon cancer only in the absence of FA supplements or FA supplemented diet. Changes in B vitamin concentrations and
enzyme polymorphisms may produce unpredictable DNA methylation changes in part by varying DNA methyl transferase concentrations and
SAM/SAH concentrations i.e. folate depletion may cause global DNA hypomethylation and specific CpG hypermethylations.
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gression is well established [18,19]. Its relevance to the
genesis of prostate cancer is illustrated by methylation
of the glutathione S-transferase (GSTP1)g e n e .E p i -
methylation of the GSTP1 gene is absent in normal
prostate tissue and present in 6.4% of proliferative
inflammatory atrophy, which is the precursor lesion of
prostate cancer. GSTP1 hypermethylation is observed in
70% of patients with high-grade prostatic intra-epithelial
neoplasia (a marker lesion associated with the subse-
quent development of prostate cancer) and in 90% of
patients with prostate cancer [20].
In 2009, Figueiredo et al. [8] reported the results of
administering 1000 μg of FA as a supplement to 327
men compared to 316 controls for approximately 10
years. Their controlled clinical study revealed an almost
threefold higher incidence of prostate cancer in the
group that received FA supplements (25 vs. 9 patients; P
= 0.007 (logrank test) with an age-adjusted hazard ratio
of 2.63). Hultdin et al. [21], in a study conducted in
Sweden, observed that vitamin B12 supplementation was
associated with an up to threefold increase in the risk of
prostate cancer.
Yegnasubramanian et al. [22] noted that global DNA
hypomethylation occurs later than CpG island hyper-
methylation in prostate carcinogenesis. These changes
occur during prostate cancer progression and metastatic
dissemination. Thus, DNA methylation may be responsi-
ble not only for carcinogenesis but also for tumor dedif-
ferentiation as well as destabilizing genetic mutations,
leading to tumor stimulation and metastasis. Collin et
al. [16,17] found that two folate pathway polymorphisms
(MTR 2756A > G and SHMT1 1420C > T) and circulat-
ing concentrations of vitamin B12 were associated with
an increased risk of prostate cancer. Bistulfi et al. [23]
demonstrated that prostate cells are highly susceptible
to genetic and epigenetic changes caused by mild folate
depletion.
E-cadherin, a transmembrane glycoprotein and a
member of the cadherin family of cell adhesion mole-
cules, mediates cell-cell adhesion via calcium-dependent
interactions. E-cadherin, which may function as a tumor
suppressor gene in tumor invasion and metastasis, is
decreased or absent in many cancers and is predictive of
tumor progression and poor patient outcome. In pros-
tate cancer, decreased expression of E-cadherin corre-
lates with hypermethylation of its promoter in patients’
samples and human cell lines as well [24]. Pellis et al.
[25] noted that incubation in the presence of high levels
of FA (100 ng/mL) is associated with a marked decrease
in E-cadherin expression in colon cancer cells in vitro
[25].
As discussed above with regard to our patient, numer-
ous possible FA and vitamin B12 pathways may have
modulated prostate tumor growth. Ours is not the first
patient with prostate cancer in whom we observed a
response to a B vitamin [7]. We believe that the changes
in PSA observed in our patient may have been related
to changes in his serum levels of folate and/or vitamin
B12.
Docetaxel therapy was deemed ineffective because of
the absence of a PSA response during 18 weeks of
administration. However, because the PSA decline
occurred after withdrawal of B vitamins during doce-
taxel administration, the drug was continued for fear
that there was a possible unknown relationship between
it and the B vitamins. A search of the literature did not
support a direct metabolic interaction between docetaxel
or other taxanes and B vitamers; however, there is sup-
port for mediation of chemotherapy resistance to many
drugs, including docetaxel, via DNA epimethylation
[26-28]. We therefore consider the reversal of docetaxel
resistance by folate/vitamin B12-mediated changes in
DNA epimethylation to be possible. It is for this reason
that our patient continues to receive docetaxel on the
original schedule.
Testosterone and folate metabolism
In the rat, castration caused marked changes in the con-
tent and distribution of various folate coenzymes in
prostate tissue, which were reversed by testosterone
replacement [29]. Castration caused suppression of the
activity of prostatic DHF reductase (DHFR), a major
rate-limiting enzyme, as well as 10-formyl-THF synthase
and SHMT. Cytoplasmic SHMT acts in concert with
vitamin B6 as a metabolic switch with at least three
functions (Figure 2): (1) it preferentially supplies one-
carbon units for DNA-thymidylate synthesis by favoring
the conversion of glycine to serine, (2) it lowers methy-
lene-THF used for SAM synthesis by preferring serine
synthesis, and (3) it essentially sequesters 5-methyl-
THF, thus sacrificing SAM synthesis [30]. The adminis-
tration of testosterone restored the enzymatic activities
to close to normal values. First described by Rovinetti et
al. in 1972 [29], these castration-related changes, if pre-
sent in human prostate tissue, could produce powerful
metabolic and genetic changes modulated by the testos-
terone level of the patient.
There are several metabolic inter-relationships
between FA and its vitamers aimed at the shuttling of
methyl (CH3-) groups to support the synthesis of DNA-
thymine and to deliver methyl groups to the universal
methylator SAM. The other B vitamins, B2,B 6,a n dB 12
plus methionine, a diet-supplied amino acid, as well as
choline (eventually metabolized to methyl groups), sup-
port methyl group generation and folate metabolism.
SAM delivers the methyl groups responsible for promo-
ter CpG islands and global DNA cytosine
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Page 5 of 7epimethylation. Epimethylation of a gene promoter
region switches off transcription of the gene’se x o n ( s ) .
Exon transcription yields mRNA synthesis which will
eventually lead to synthesis of regulatory proteins/
enzymes.
Conclusion
Our patient’s clinical course suggests that high doses of
B vitamins (FA/folate and vitamin B12) may modulate
the course of PSA failure in castrate-resistant/refractory
prostate cancer. Our patient’s ingestion of large amounts
of FA/folate and vitamin B12 was associated with PSA
acceleration, while withdrawal of the supplements was
associated with a significant PSA decline. Whether this
result was secondary to the perturbation of the outlined
metabolic interactions of B vitamers (Figure 2), due to
DNA epimethylation with associated changes in gene
expression, or due to other factors is unknown. The
hypothesis of a yet to be discovered interaction with
docetaxel is entertained as well. Studies of patient use of
health store supplements, many of which are known to
affect DNA metabolism and DNA methylation markers,
have revealed that up to 50% of cancer patients ingest
large doses of vitamins and other supplements, such as
probiotics, which contain “safe” bacteria that generate
copious amounts of folates within the bowel. A recent
study in our clinic revealed that a majority of cancer
patients present with hypervitaminosis or hypovitamino-
sis of at least one or more of the B vitamins noted in
Figure 2. As we have discussed herein, castration, drugs,
diet, vitamin supplements, and probiotics may modulate
tumor cell metabolism as well as gene expression by
epimethylation and synthesis of DNA. We are con-
cerned about the finding that many gas stations and
liquor stores in the USA sell so-called “quick energy”
liquid supplements that contain large amounts of B vita-
mins, including vitamins B6 and B12 and FA.
Patient’s perspective
“I was alarmed to see a steady increase in my PSA
while undergoing chemotherapy. I had been taking a
dietary supplement containing large amounts of vita-
min B12 and folate. When I learned of the relationship
of large amounts of folate to increasing PSA, I imme-
diately stopped taking the supplement. My wife and I
searched the Internet to find foods that were low in
natural folate, and avoided those foods high in folate.
When I found out the government had mandated the
addition of folic acid to basically all products contain-
ing flour and grains since 1998 I was surprised and
dismayed. We quickly learned to read the food content
labels on packaging, and found that many foods con-
tained folic acid. Avoiding folic acid supplemented
foods meant that nearly all baked goods, cereals,
crackers, pasta, egg noodles, stuffing mix, white rice,
bagels, flour tortillas, sandwiches, burger rolls, dinner
rolls, doughnuts, pizza, pies and cakes were off limits.
M yw i f e ,w h ol o v e st ob a k e ,f o u n do r g a n i cf l o u rt h a t
was not supplemented, and used that exclusively to
make bread, cookies, pies, cakes, pizza dough, etc.
Happily, doing something as simple as reducing FA
intake, allowed the chemotherapy to rapidly reduce my
PSA to the lowest level in years.”
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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